Video
Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong
Author(s):
OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.
Today-
We are reporting from the 2021 ASCO Annual Meeting!
We have been highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Neal Shore about some pivotal prostate cancer abstracts, Dr. Loretta Nastoupil on the latest in lymphoma, and Dr. Sandy Wong on the magnitude of multiple myeloma research being presented.
Welcome to OncLive News Network! I’m Gina Mauro.
In the phase 2 PANAMA trial, the addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, as seen in the interim findings from the phase 2 ELARA trial.
The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers, according to data from a first-in-human phase 1 trial.
Phase 2 findings demonstrated that pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer MIBC.
In 3.5-year follow-up of the KEYNOTE-426 trial, the frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.
In uterine cancer, the combination of pertuzumab and trastuzumab elicited a 37% disease control rate in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, according to results from ASCO’s TAPUR study.
Please be sure to check out more of our coverage from the 2021 ASCO Annual Meeting at OncLive.com.
That’s all for today. We’re signing off from the 2021 ASCO Annual Meeting. Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.
